CAR-T (Shanghai) Biotechnology Co., Ltd.
This is a single center phase I / II clinical trial. Randomized, blind and positive drug parallel control were used to evaluate the safety and effectiveness of dental pulp mesenchymal cell injection in the treatment of depression 8 weeks after administration
Depression
Dental pulp mesenchymal cell injection
Dental pulp mesenchymal cell vehicle
fluoxetine hydrochloride capsule
Not Applicable
This is a single center phase I / II clinical trial. Randomized, blind and positive drug parallel control were used to evaluate the safety and effectiveness of dental pulp mesenchymal cell injection in the treatment of depression 8 weeks after administration. The positive control drug was fluoxetine hydrochloride capsule with a dose of 40mg / day.The study included screening period (no more than 4 weeks), treatment period (8 weeks), and follow-up period (12 months).Subjects who met the inclusion criteria and did not meet the exclusion criteria were randomly assigned to the experimental group and the control group in the ratio of 1:1.During 8 weeks of treatment, subjects in the experimental group were given dental pulp mesenchymal cell injection + fluoxetine hydrochloride capsule simulant; The subjects in the control group were given dental pulp mesenchymal cell injection vehicle + fluoxetine hydrochloride capsule. During the treatment period, dental pulp mesenchymal cell injection / vehicle was injected intravenously for 4 times at an interval of 2 weeks (once at 0, 2, 4 and 6 weeks respectively); At the same time, fluoxetine hydrochloride capsule / simulant was taken orally every day during the treatment period.The efficacy and safety were evaluated 2 weeks after intravenous administration (visit and evaluation at 2, 4, 6 and 8 weeks respectively). Safety telephone follow-up was conducted 4 weeks (10th week), 6 months and 12 months after the last intravenous administration.}}
Study Type : | Interventional |
Estimated Enrollment : | 48 participants |
Masking : | Single |
Primary Purpose : | Treatment |
Official Title : | Safety and Efficacy of Dental Pulp Mesenchymal Cells in the Treatment of Depression: |
Actual Study Start Date : | January 1, 2022 |
Estimated Primary Completion Date : | December 30, 2023 |
Estimated Study Completion Date : | June 30, 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: Test group Dental pulp mesenchymal cell injection (dose: 0.1u/kg) + fluoxetine hydrochloride |
Drug: Dental pulp mesenchymal cell injection Drug: fluoxetine hydrochloride capsule |
Active Comparator: control group Dental pulp mesenchymal cell injection vehicle + fluoxetine hydrochloride capsule |
Drug: Dental pulp mesenchymal cell vehicle Drug: fluoxetine hydrochloride capsule |
Ages Eligible for Study: | 18 Years to 60 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.